Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
Epistemonikos ID: 2e9a062b696d8d9d7393ed6364c4a074b91d853c
First added on: May 21, 2024